Quick Answer
Yubo International Biotech Ltd reported Gross Profit of $8.2 thousand for the year ending 2025.
- Yubo International Biotech Ltd showed an increase of +208.3% in Gross Profit from 2024 to 2025.
- This data is from Yubo International Biotech Ltd's annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: $0.00 | Q2 2020: $253.4 thousand | Q3 2020: $131.5 thousand | Q1 2021: $315.6 thousand | Q2 2021: $213.0 thousand | Q3 2021: $73.2 thousand | Q1 2022: $8.3 thousand | Q2 2022: $5.9 thousand | Q3 2022: $9.6 thousand | Q1 2023: $57.7 thousand | Q2 2023: $885.00 | Q3 2023: $344.1 thousand | Q1 2024: $2.7 thousand | Q2 2024: $0.00 | Q3 2024: $0.00 | Q1 2025: $0.00 | Q2 2025: $0.00 | Q3 2025: $0.00.
- Over the full 6 years of available data (2020 to 2025), Yubo International Biotech Ltd's Gross Profit has declined by 99.3%.
- Historical annual values: Fiscal year 2025: $8.2 thousand | Fiscal year 2024: $2.6 thousand | Fiscal year 2023: $419.2 thousand | Fiscal year 2022: $52.7 thousand | Fiscal year 2021: $820.6 thousand | Fiscal year 2020: $1.24 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: